NCT01240928撤回1 期
A Phase Ib Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Tolerability of MK-2206 given in combination with exemestane +/- goserelin, as measured by maximum tolerated dose (MTD).
研究概览
简要总结
This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor-positive metastatic breast cancer.
详细描述
The phase II portion of this trial will be listed under a separate NCT number.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Clinical stage IV invasive mammary carcinoma, documented by histological analysis, ER-positive and/or PR-positive by immunohistochemistry (IHC), previous endocrine therapy in the metastatic setting or had metastatic recurrence within 6 months of adjuvant endocrine therapy. May have measurable or non-measurable disease, both are allowed. Any number of prior hormone or chemotherapy agents are acceptable
- •Female and ≥ 18 years of age on the day of signing informed consent
- •Performance status of 0 or 1 on the ECOG Performance Scale
- •Adequate organ function as indicated by the following laboratory values:
- •Hematological:
- •Absolute neutrophil count (ANC) ≥ 1,500 /μL
- •Platelets ≥ 100,000 /μL
- •Hemoglobin ≥ 9 g/dL
- •Serum creatinine or calculated creatinine clearance† - ≤ 1.5 x upper limit of normal (ULN) OR ≥60 mL/min for patients with creatinine levels > 1.5 x institutional ULN
- •Serum total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 x ULN
- •AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN or ≤5 x ULN in patients with known liver metastasis
- •Coagulation:
- •Prothrombin time (PT)/INR ≤ 1.2 x ULN
- •Partial thromboplastin time (PTT) ≤ 1.2 x ULN
- •HBA1C ≤ 8%
- •† Creatinine clearance calculated per institutional standard
- •‡ Fasting defined as at least 8 hours without oral intake
- •Female patient of childbearing potential must have negative serum or urine pregnancy test β-hCG within 72 hours prior to receiving the first dose of study medication
- •Post-menopausal female subjects defined prior to protocol enrollment by any of the following:
- •At least 55 years of age
- •Under 55 years of age and amenorrheic for at least 12 months or follicle-stimulating hormone (FSH) values ≥ 40 IU/L and estradiol levels < or equal to 20IU/L
- •Prior bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months
- •Patient, or the patient's legal representative, has voluntarily agreed to participate by giving written informed consent
- •Able to swallow capsules and has no surgical or anatomical condition that will preclude swallowing and absorbing oral medications on an ongoing basis
- •May receive concurrent radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is initiated prior to study entry. Those who have received prior radiotherapy must have recovered from any toxicity induced by this treatment (toxicity grade ≤ 1)
排除标准
- •Chemotherapy, radiotherapy, or biological therapy within 3 weeks (6 weeks for nitrosoureas, mitomycin C or bevacizumab), or not recovered from the adverse events due to previous agents administered more than 4 weeks prior to Study Day
- •If residual toxicity from prior treatment,toxicity must be ≤ Grade 1
- •Must be at least 4 weeks post-major surgical procedure, and all surgical wounds must be fully healed
- •Currently participating or has participated in a study with an investigational compound or device within 30 days of Study Day 1
- •Known active CNS metastases and/or carcinomatous meningitis. However, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for at least 1 month prior to entry as defined as: (1) no evidence of new or enlarging CNS metastasis (2)off steroids used to minimize surrounding brain edema
- •Primary central nervous system tumor
- •Known hypersensitivity to the components of study drug or its analogs
- •History or current evidence of clinically significant heart disease including:
- •congestive heart failure, unstable angina pectoris,
- •cardiac arrhythmia,
- •history or current evidence of a myocardial infarction during the last 6 months,and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator,
- •baseline QTc prolongation > 450 msec (Bazett's Formula). Medications included in Arizona CERT Lists 1 and 2 (Appendix D) must be excluded. The concomitant use of drugs that are associated with increased risk for QT prolongation should be avoided in patients with congenital long QT syndrome (Appendix D, Arizona CERT List 3). Similarly, the concomitant use of drugs that are weakly associated with QT prolongation should be generally avoided (Appendix D, Arizona CERT List 4). Arizona CERT List 3 and 4 drugs should be used at the discretion of the Investigator and restricted where applicable. Any therapy given with these drugs should be used with caution, and patients receiving these medications should be carefully monitored.
- •Evidence of clinically significant bradycardia (HR <50), or a history of clinically significant bradyarrhythmias such as sick sinus syndrome, 2nd degree AV block (Mobitz Type 2), or patients taking beta blockers, non-dihydropyridine calcium channel blockers, or digoxin
- •Uncontrolled hypertension (i.e., 160/90 mHg SiBP). Patients who are controlled on antihypertensive medication will be allowed to enter the study
- •At significant risk for hypokalemia (e.g., patients on high dose diuretics, or with recurrent diarrhea)
- •Poorly controlled diabetes defined as HbA1C > 8%
- •History or current evidence of any condition, therapy, or lab abnormality that might confound the study results, interfere with the patient's participation for the full study duration, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
- •Known psychiatric or substance abuse disorders that would interfere with cooperation with trial requirements
- •Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse
- •Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
- •Human Immunodeficiency Virus (HIV)-positive
- •Known history of Hepatitis B or C or active Hepatitis A
- •Symptomatic ascites or pleural effusion. Patient who is clinically stable following treatment for these conditions is eligible
- •Receiving treatment with oral corticosteroids (note: inhaled corticosteroids are permitted)
研究组 & 干预措施
MK-2206 + exemestane +/- goserelin
Experimental
Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
干预措施: MSK-2206 (Drug)
MK-2206 + exemestane +/- goserelin
Experimental
Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
干预措施: Exemestane (Drug)
MK-2206 + exemestane +/- goserelin
Experimental
Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
干预措施: Goserelin (Drug)
结局指标
主要结局
Tolerability of MK-2206 given in combination with exemestane +/- goserelin, as measured by maximum tolerated dose (MTD).
时间窗: at 4 weeks
The MTD will be defined as the highest dose tested in which a dose-limiting toxicity is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels.
次要结局
- Number of participants with adverse events as a measure of safety of MK-2206 when combined with exemestane +/- goserelin(At 4 weeks)
- Characterize the effect of MK-2206 in combination with exemestane +/- goserelin based on PI3K, AKT, and PTEN mutations, as measured by immunohistochemistry and the SNaPshot assay.(After collection of tumor tissue)
研究者
Vandana Abramson
Assistant Professor of Medicine, Medical Oncologist
Vanderbilt-Ingram Cancer Center
相似试验
已完成
1 期
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaAccelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative DisorderAggressive NK-cell LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChildhood Burkitt LymphomaChildhood Chronic Myelogenous LeukemiaChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisChildhood Immunoblastic Large Cell LymphomaChildhood Nasal Type Extranodal NK/T-cell LymphomaChronic Neutrophilic LeukemiaChronic Phase Chronic Myelogenous LeukemiaIntraocular LymphomaMast Cell LeukemiaMyeloid/NK-cell Acute LeukemiaNoncutaneous Extranodal LymphomaPrimary Central Nervous System Hodgkin LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaProgressive Hairy Cell Leukemia, Initial TreatmentRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRelapsing Chronic Myelogenous LeukemiaSecondary Acute Myeloid LeukemiaSmall Intestine LymphomaSplenic Marginal Zone LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificWaldenström MacroglobulinemiaChronic Myelomonocytic LeukemiaProlymphocytic LeukemiaPost-transplant Lymphoproliferative DisorderAcute Undifferentiated LeukemiaJuvenile Myelomonocytic LeukemiaChronic Eosinophilic LeukemiaNCT01231919National Cancer Institute (NCI)45
已完成
1 期
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerEstrogen Receptor PositiveInvasive Breast CarcinomaRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7NCT01344031National Cancer Institute (NCI)31
已完成
1 期
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast CancerAdult Solid NeoplasmRecurrent Breast CarcinomaStage IV Breast CancerNCT01263145National Cancer Institute (NCI)34
已完成
1 期
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerHER2-positive Breast CancerRecurrent Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerUnspecified Adult Solid Tumor, Protocol SpecificMale Breast CancerNCT01245205National Cancer Institute (NCI)28
终止
1 期
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryAdenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerRecurrent Breast CancerRecurrent Esophageal CancerRecurrent Gastric CancerStage IIIC Breast CancerStage IIIC Esophageal CancerStage IIIC Gastric CancerStage IV Breast CancerStage IV Esophageal CancerStage IV Gastric CancerMale Breast CancerNCT01705340National Cancer Institute (NCI)60